Vidaza Related Published Studies
Well-designed clinical trials related to Vidaza (Azacitidine Subcutaneous)
Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group. [2011.08]
Effects of azacitidine compared with conventional care regimens in elderly (>/= 75 years) patients with higher-risk myelodysplastic syndromes. [2010.12]
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. [2010.10.28]
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. [2010.08]
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. [2010.04]
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. [2010.02.01]
Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. [2010.01]
Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. [2009.04.10]
A limited number of 5-azacitidine cycles can be effective treatment in MDS. [2009.03]
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. [2009.03]
A limited number of 5-azacitidine cycles can be effective treatment in MDS. [2008.08.12]
Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. [2005.05.15]
Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. [2005.05]
FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. [2005.03]
Well-designed clinical trials possibly related to Vidaza (Azacitidine Subcutaneous)
Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancer. [2011.10]
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. [2011.05.20]
Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes. [2009.02]
Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. [2008.02.15]
Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. [2007.08.01]
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. [2007.03.15]
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. [2007.01.15]
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. [2007.01.01]
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. [2006.04.15]
Other research related to Vidaza (Azacitidine Subcutaneous)
Subcutaneous 5-Azacitidine Treatment of Naturally Occurring Canine Urothelial Carcinoma: A Novel Epigenetic Approach to Human Urothelial Carcinoma Drug Development. [2011.11.16]
A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes. [2011.11.04]
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. [2011.10.28]
Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. [2011.09]
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. [2011.08.20]
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. [2011.07]
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. [2011.06.20]
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. [2011.06.15]
Activity of azacitidine in chronic myelomonocytic leukemia. [2011.06.15]
Azacitidine adverse effects in patients with myelodysplastic syndromes. [2011.06]
Adverse effects of azacitidine: onset, duration, and treatment. [2011.06]
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. [2011.04.15]
Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia. [2011.03]
DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome. [2011.02]
Thrice weekly azacitidine does not improve hematological responses in lower-risk
myelodysplastic syndromes: a study of the Hoosier Oncology Group. [2011]
Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. [2010.09]
5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. [2010.08]
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. [2010.07.29]
Phase II study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. [2010.07.14]
Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment. [2010.07]
Effects of azacitidine compared with conventional care regimens in elderly (>/=75 years) patients with higher-risk myelodysplastic syndromes. [2010.05.05]
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. [2010.05.01]
Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia. [2010.05]
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. [2010.05]
Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program. [2010.03.15]
5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis. [2010.02]
Fabrication of novel hepatoma-targeting microdisks by hydrogen bond-assisted self-assembly of an azacitidine-conjugating amphiphilic random copolymer. [2010.02]
5-Azacytidine/Azacitidine. [2010]
Report of a phase 1/2 study of a combination of azacitidine and cytarabine in
acute myelogenous leukemia and high-risk myelodysplastic syndromes. [2010]
5-azacitidine prolongs overall survival in patients with myelodysplastic
syndrome--a systematic review and meta-analysis. [2010]
Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration-resistant prostate cancer. [2009.12.01]
Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes. [2009.12]
Azacitidine in lower-risk myelodysplastic syndromes. [2009.12]
Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents. [2009.12]
5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - systematic review and meta-analysis. [2009.09.22]
A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. [2009.09]
Fabrication of novel hepatoma-targeting microdisks by hydrogen bond-assisted self-assembly of an azacitidine-conjugating amphiphilic random copolymer. [2009.07.22]
Azacitidine for the treatment of myelodysplastic syndrome. [2009.07]
Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. [2009.06]
Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. [2009.05.01]
Sorafenib: a review of its use in advanced hepatocellular carcinoma. [2009]
Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. [2008.11]
A pilot pharmacokinetic study of oral azacitidine. [2008.09]
Azacitidine and the beginnings of therapeutic epigenetic modulation. [2008.08]
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. [2008.05]
Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. [2008.04]
Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy. [2007.12]
The role of azacitidine in the treatment of myelodysplastic syndromes. [2007.12]
Azacitidine-associated hyperthermia and interstitial pneumonitis in a patient with myelodysplastic syndrome. [2007.12]
Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. [2007.09]
Azacitidine pharmacokinetics in an adolescent patient with renal compromise. [2007.05]
Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. [2007.02]
Treatment of acute myelogenous leukemia with outpatient azacitidine. [2006.10.15]
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. [2006.08.20]
Azacitidine: a novel agent for myelodysplastic syndromes. [2005.08.01]
Advances in myelodysplastic syndrome: nursing implications of azacitidine. [2005.08]
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. [2005.06.10]
Azacitidine. [2005.05]
Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome. [2005.05]
Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders. [2005]
Other possibly related research studies
Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. [2007.01.01]
Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer. [2007.01]
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. [2006.11.14]
DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML. [2006.10]
Global DNA and p53 region-specific hypomethylation in human colonic cells is induced by folate depletion and reversed by folate supplementation. [2006.11]
Chemotherapeutic agents for colorectal cancer with a defective mismatch repair system: the state of the art. [2006.12]
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. [2006.10.01]
Inhibitors of histone deacetylases and DNA methyltransferases alter imprinted gene regulation in embryonic stem cells. [2006.09]
The genomics of new drugs in sickle cell disease. [2006.09]
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. [2006.11.15]
Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. [2006]
Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. [2006.06.15]
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. [2006.06.15]
New strategies in chronic myeloid leukemia. [2006.05]
Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine. [2006.07]
Lubiprostone. [2006]
Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. [2006.06.01]
DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. [2006.05.15]
|
